Cargando…

Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation

BACKGROUND: Dabigatran is a direct thrombin inhibitor approved by the FDA in October 2010 for the treatment of nonvalvular atrial fibrillation. Little is known regarding patient adherence to this therapy. OBJECTIVE: To examine adherence and persistence to dabigatran among adults with atrial fibrilla...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhou, Meijia, Chang, Hsien-Yen, Segal, Jodi B., Alexander, G. Caleb, Singh, Sonal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Academy of Managed Care Pharmacy 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397607/
https://www.ncbi.nlm.nih.gov/pubmed/26521117
http://dx.doi.org/10.18553/jmcp.2015.21.11.1054
_version_ 1785083945975545856
author Zhou, Meijia
Chang, Hsien-Yen
Segal, Jodi B.
Alexander, G. Caleb
Singh, Sonal
author_facet Zhou, Meijia
Chang, Hsien-Yen
Segal, Jodi B.
Alexander, G. Caleb
Singh, Sonal
author_sort Zhou, Meijia
collection PubMed
description BACKGROUND: Dabigatran is a direct thrombin inhibitor approved by the FDA in October 2010 for the treatment of nonvalvular atrial fibrillation. Little is known regarding patient adherence to this therapy. OBJECTIVE: To examine adherence and persistence to dabigatran among adults with atrial fibrillation. METHODS: We used IMS Health’s LifeLink Health Plan Claims Database from 2010 to 2012 to identify patients with atrial fibrillation who were new users of dabigatran. We derived adherence and persistence for continuously enrolled patients at 6 months, 9 months, and 12 months of follow-up. We measured adherence using the medication possession ratio (MPR), defined as individuals with MPRs of 0.80 or greater as adherent, and examined persistence by identifying individuals with gaps in drug possession of 60 days or greater. RESULTS: Of 5,951 adults with atrial fibrillation who were new users of dabigatran, 49% had prevalent atrial fibrillation and at least 6 months of continuous follow-up. Of these, 89% used dabigatran as the only oral anticoagulant, whereas the remainder filled prescriptions for at least 1 other oral anticoagulant during the follow-up period. Among those using dabigatran alone (n = 2,713), the mean MPR was 0.73 (standard error = 0.30), 41% were nonadherent with therapy, and 32% had gaps of 60 days or greater. Among those observed for 9 (or 12) months who used dabigatran alone, rates of nonadherence were 47% (49%), whereas 48% (49%) discontinued therapy during follow-up. Rates of adherence and persistence were similar for patients with incident atrial fibrillation. CONCLUSIONS: Nonadherence to dabigatran was common among patients with atrial fibrillation. Future studies are needed to understand the reasons for nonadherence.
format Online
Article
Text
id pubmed-10397607
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Academy of Managed Care Pharmacy
record_format MEDLINE/PubMed
spelling pubmed-103976072023-08-04 Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation Zhou, Meijia Chang, Hsien-Yen Segal, Jodi B. Alexander, G. Caleb Singh, Sonal J Manag Care Spec Pharm Research BACKGROUND: Dabigatran is a direct thrombin inhibitor approved by the FDA in October 2010 for the treatment of nonvalvular atrial fibrillation. Little is known regarding patient adherence to this therapy. OBJECTIVE: To examine adherence and persistence to dabigatran among adults with atrial fibrillation. METHODS: We used IMS Health’s LifeLink Health Plan Claims Database from 2010 to 2012 to identify patients with atrial fibrillation who were new users of dabigatran. We derived adherence and persistence for continuously enrolled patients at 6 months, 9 months, and 12 months of follow-up. We measured adherence using the medication possession ratio (MPR), defined as individuals with MPRs of 0.80 or greater as adherent, and examined persistence by identifying individuals with gaps in drug possession of 60 days or greater. RESULTS: Of 5,951 adults with atrial fibrillation who were new users of dabigatran, 49% had prevalent atrial fibrillation and at least 6 months of continuous follow-up. Of these, 89% used dabigatran as the only oral anticoagulant, whereas the remainder filled prescriptions for at least 1 other oral anticoagulant during the follow-up period. Among those using dabigatran alone (n = 2,713), the mean MPR was 0.73 (standard error = 0.30), 41% were nonadherent with therapy, and 32% had gaps of 60 days or greater. Among those observed for 9 (or 12) months who used dabigatran alone, rates of nonadherence were 47% (49%), whereas 48% (49%) discontinued therapy during follow-up. Rates of adherence and persistence were similar for patients with incident atrial fibrillation. CONCLUSIONS: Nonadherence to dabigatran was common among patients with atrial fibrillation. Future studies are needed to understand the reasons for nonadherence. Academy of Managed Care Pharmacy 2015-11 /pmc/articles/PMC10397607/ /pubmed/26521117 http://dx.doi.org/10.18553/jmcp.2015.21.11.1054 Text en © 2015, Academy of Managed Care Pharmacy. All rights reserved. https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Research
Zhou, Meijia
Chang, Hsien-Yen
Segal, Jodi B.
Alexander, G. Caleb
Singh, Sonal
Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
title Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
title_full Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
title_fullStr Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
title_full_unstemmed Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
title_short Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation
title_sort adherence to a novel oral anticoagulant among patients with atrial fibrillation
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10397607/
https://www.ncbi.nlm.nih.gov/pubmed/26521117
http://dx.doi.org/10.18553/jmcp.2015.21.11.1054
work_keys_str_mv AT zhoumeijia adherencetoanoveloralanticoagulantamongpatientswithatrialfibrillation
AT changhsienyen adherencetoanoveloralanticoagulantamongpatientswithatrialfibrillation
AT segaljodib adherencetoanoveloralanticoagulantamongpatientswithatrialfibrillation
AT alexandergcaleb adherencetoanoveloralanticoagulantamongpatientswithatrialfibrillation
AT singhsonal adherencetoanoveloralanticoagulantamongpatientswithatrialfibrillation